COMPASS Pathways and MAPS Public Benefit Corporation, MAPS PBC, announced that the American Medical Association, AMA, has approved a Current Procedural Terminology, CPT, III code for psychedelic therapies. The full details of the code are expected to be released by the AMA in July 2023 and the code will go into effect when it is published on January 1, 2024. Once effective, the CPT code will provide physicians and other qualified healthcare professionals a means to code and seek reimbursement for delivering psychedelic therapies. The application for the new CPT III code was the result of a collaboration between MAPS PBC and COMPASS Pathways to facilitate reimbursement and ultimately access to psychedelic therapies in the US, if approved by the US Food Drug Administration, FDA. Both companies are working to develop and, subject to FDA approval, commercialize psychedelics as part of a new treatment paradigm for individuals with mental health conditions. COMPASS Pathways is conducting a phase 3 program of investigational COMP360 psilocybin therapy in treatment-resistant depression, TRD, having already published positive results in the New England Journal of Medicine from its phase 2b study of COMP360 in TRD, in the largest study of its kind. MAPS PBC has completed two phase 3 clinical trials evaluating MDMA-assisted therapy as a potential treatment for post-traumatic stress disorder, both of which met their pre-specified primary and secondary endpoints. This new code may provide a mechanism by which these new treatments being developed by COMPASS and MAPS PBC could be reimbursed if they are approved by the FDA. "This is a major step forward to enabling broad and equitable access to psychedelic therapies," said Kabir Nath, CEO, COMPASS Pathways. "This collaboration with MAPS PBC to develop a new CPT code aims to ensure that psychedelic therapies, if approved, could be integrated into healthcare systems, reimbursed by payers, and made available to the people who need them."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CMPS:
- Short Report: Bears boost Vivid Seats position to record high as stock bottoms
- Rising High: Exclusive talk with biotech company PharmAla
- Here’s What You Missed in Cannabis This Week
- COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference
- Rising High: Exclusive talk with multinational cannabis operator Clever Leaves